APM
PRLD icon

Avidity Partners Management’s Prelude Therapeutics PRLD Stock Holding History

Avidity Partners Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-890,000
Closed -$1.84M – 78
2024
Q3 		$1.84M Buy
+890,000
New +$4.12M 0.09% 77

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Avidity Partners Management's PRLD Position: Q4 2024 in Review

Avidity Partners Management sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 890,000 shares — an estimated $1.84M sold.

Avidity Partners Management first reported a position in PRLD in Q3 2024 and held it in 1 quarter. The position peaked at $1.84M in Q3 2024. 61 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

  • Avidity Partners Management reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 890,000 Prelude Therapeutics shares in Q4 2024, an estimated $1.84M.
  • Avidity Partners Management first reported a position in Prelude Therapeutics in Q3 2024 and held it in 1 quarter.
  • Avidity Partners Management's Prelude Therapeutics position peaked at $1.84M in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.